Prime time for prospective randomized trials of targeted therapies with validated targets in lung cancer: FDA perspective

被引：0

作者：

Malik, Shakun ^{[1
]}

Justice, Robert ^{[1
]}

Sridhara, Rajeshwari ^{[1
]}

Waxman, Ian ^{[1
]}

Pazdur, Richard ^{[1
]}

机构：

[1] US FDA, CDER, Silver Spring, MD USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S235 / S236

页数：2

共 50 条

[31] Use of progression-free survival (PES) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective
Malik, S. M.
Ibrahim, A.
Sridhara, R.
Justice, R. L.
Pazdur, R.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[32] Compliance with PET acquisition protocols for therapeutic monitoring of molecular targeted therapies in lung cancer: are multi-center international trials in this setting feasible?
Hicks, Rodney J.
Mileshkin, Linda
Binns, David S.
Callahan, Jason
Macfarlane, David
Yu, Wei
Pirzkall, Andrea
Fine, Bernard
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S479 - S479
[33] Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials
Fiteni, Frederic
Paillard, Marie-Justine
Westeel, Virginie
Bonnetain, Franck
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 167 - 173
[34] PARTICIPANTS IN PROSPECTIVE, RANDOMIZED CLINICAL-TRIALS FOR RESECTED NON-SMALL CELL LUNG-CANCER HAVE IMPROVED SURVIVAL COMPARED WITH NONPARTICIPANTS IN SUCH TRIALS
DAVIS, S
WRIGHT, PW
SCHULMAN, SF
HILL, LD
PINKHAM, RD
JOHNSON, LP
JONES, TW
KELLOGG, HB
RADKE, HM
SIKKEMA, WW
JOLLY, PC
HAMMAR, SP
CANCER, 1985, 56 (07) : 1710 - 1718
[35] Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
Tomasini, Pascale
Greillier, Laurent
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S323 - S326
[36] Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform
Mayo de las Casas, Clara
Garzon-Ibanez, Monica
Jordana-Ariza, Nuria
Viteri-Ramirez, Santiago
Moya-Horno, Irene
Karachaliou, Niki
Yeste, Zaira
Campos, Raquel
Villatoro, Sergi
Balada-Bel, Ariadna
Garcia-Pelaez, Beatriz
Reguart, Noemi
Teixido, Cristina
Jantus, Eloisa
Calabuig, Silvia
Aguado, Cristina
Gimenez-Capitan, Ana
Roman-Llado, Ruth
Perez-Rosado, Ana
Jose Catalan, Maria
Bertran-Alamillo, Jordi
Garcia-Roman, Silvia
Rodriguez, Sonia
Alonso, Lidia
Aldeguer, Erika
Martinez-Bueno, Alejandro
Gonzalez-Cao, Maria
Aguilar Hernandez, Andres
Garcia-Mosquera, Juan
de los Llanos Gil, Maria
Fernandez, Manuel
Rosell, Rafael
Angel Molina-Vila, Miguel
TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S3 - S15
[37] Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials
Qi, Wei-Xiang
Fu, Shen
Zhang, Qing
Guo, Xiao-Mao
JOURNAL OF CHEMOTHERAPY, 2015, 27 (03) : 181 - 187
[38] Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials
Harada, Toshiyuki
Amano, Toraji
Ikari, Tomoo
Takamura, Kei
Ogi, Takahiro
Fujikane, Toshiaki
Fujita, Yuka
Taima, Kageaki
Tanaka, Hisashi
Sasaki, Takaaki
Okumura, Shunsuke
Sugawara, Shunichi
Yokouchi, Hiroshi
Yamada, Noriyuki
Morikawa, Naoto
Dosaka-Akita, Hirotoshi
Isobe, Hiroshi
Nishimura, Masaharu
FRONTIERS IN PHARMACOLOGY, 2018, 8
[39] Randomized phase III trials of standard chemotherapy with or without targeted agents as first-line therapy in non-small cell lung cancer
Hoang, T.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[40] Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer
Blumenthal, G. M.
Gong, Y.
Kehl, K.
Mishra-Kalyani, P.
Goldberg, K. B.
Khozin, S.
Kluetz, P. G.
Oxnard, G. R.
Pazdur, R.
ANNALS OF ONCOLOGY, 2019, 30 (05) : 830 - 838

← 1 2 3 4 5 →